GB Sciences, Inc. (OTCMKTS:GBLX – Get Rating) was the target of a significant growth in short interest in April. As of April 15th, there was short interest totalling 24,500 shares, a growth of 175.3% from the March 31st total of 8,900 shares. Based on an average trading volume of 798,300 shares, the short-interest ratio is currently 0.0 days.
Shares of GB Sciences stock traded down $0.00 during trading hours on Friday, hitting $0.03. The company’s stock had a trading volume of 26,672 shares, compared to its average volume of 257,174. The business has a 50 day moving average price of $0.03 and a two-hundred day moving average price of $0.03. GB Sciences has a 12-month low of $0.02 and a 12-month high of $0.07.
GB Sciences, Inc engages in the research and development of cannabinoid medicines in North America and Europe. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc and changed its name to GB Sciences, Inc in October 2016.
- Get a free copy of the StockNews.com research report on GB Sciences (GBLX)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- Iridium Communications Stock is Ready to Return to Orbit
Receive News & Ratings for GB Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GB Sciences and related companies with MarketBeat.com's FREE daily email newsletter.